ECSP055852A - Tratamiento del trastorno por déficit de atención con hiperactividad - Google Patents

Tratamiento del trastorno por déficit de atención con hiperactividad

Info

Publication number
ECSP055852A
ECSP055852A EC2005005852A ECSP055852A ECSP055852A EC SP055852 A ECSP055852 A EC SP055852A EC 2005005852 A EC2005005852 A EC 2005005852A EC SP055852 A ECSP055852 A EC SP055852A EC SP055852 A ECSP055852 A EC SP055852A
Authority
EC
Ecuador
Prior art keywords
hyperactivity
deficit
disorder
care
treatment
Prior art date
Application number
EC2005005852A
Other languages
English (en)
Inventor
Vincent Edward Groppi Jr
Eric Jon Jacobsen
Jason Kenneth Myers
David Walter Piotrowski
Bruce Nelsen Rogers
Daniel Patrick Walker
Donn Gregory Wishka
Original Assignee
Pharmacia & Upjohn Co Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn Co Llc filed Critical Pharmacia & Upjohn Co Llc
Publication of ECSP055852A publication Critical patent/ECSP055852A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Mechanical Treatment Of Semiconductor (AREA)
  • Developing Agents For Electrophotography (AREA)
  • Liquid Crystal Substances (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención se refiere a composiciones y a procedimientos para tratar ADHD con un agonista completo de nAChR a7 y psicoestimulantes y/o inhibidores de la recaptación de monoamina.
EC2005005852A 2002-12-11 2005-06-10 Tratamiento del trastorno por déficit de atención con hiperactividad ECSP055852A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US43258602P 2002-12-11 2002-12-11

Publications (1)

Publication Number Publication Date
ECSP055852A true ECSP055852A (es) 2005-09-20

Family

ID=32507968

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2005005852A ECSP055852A (es) 2002-12-11 2005-06-10 Tratamiento del trastorno por déficit de atención con hiperactividad

Country Status (23)

Country Link
US (1) US20050107425A1 (es)
EP (1) EP1572300A1 (es)
JP (1) JP2006510663A (es)
KR (1) KR20050085538A (es)
CN (1) CN1735441A (es)
AP (1) AP2005003336A0 (es)
AU (1) AU2003283656A1 (es)
BR (1) BR0317229A (es)
CA (1) CA2509142A1 (es)
CO (1) CO5700801A2 (es)
CR (1) CR7868A (es)
EA (1) EA200500783A1 (es)
EC (1) ECSP055852A (es)
HR (1) HRP20050522A2 (es)
IS (1) IS7858A (es)
MA (1) MA27606A1 (es)
MX (1) MXPA05006336A (es)
NO (1) NO20053185L (es)
OA (1) OA12969A (es)
PL (1) PL377552A1 (es)
TN (1) TNSN05158A1 (es)
WO (1) WO2004052461A1 (es)
ZA (1) ZA200504338B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
GB0310867D0 (en) * 2003-05-12 2003-06-18 Novartis Ag Organic compounds
CA2560741C (en) 2004-03-25 2013-08-06 Memory Pharmaceuticals Corporation Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, and preparation and uses thereof
GB0424564D0 (en) * 2004-11-05 2004-12-08 Novartis Ag Organic compounds
WO2008083442A1 (en) * 2007-01-10 2008-07-17 Brc Operations Pty Limited Method for formulating combination medications for adhd
US20100056600A1 (en) * 2007-03-28 2010-03-04 Soren Ebdrup 11beta-hsd1 active compounds
SA08290475B1 (ar) 2007-08-02 2013-06-22 Targacept Inc (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
CA2715192A1 (en) * 2008-02-19 2009-08-27 Adolor Corporation Beloxepin, its enantiomers, and analogs thereof for the treatment of pain
MX2011005037A (es) 2008-11-21 2011-06-16 High Point Pharmaceuticals Llc Compuestos de adamantilo benzamida.
TW201031664A (en) 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
KR20180101641A (ko) 2010-05-17 2018-09-12 포럼 파마슈티칼즈 인크. (R)-7-클로로-N-(퀴누클리딘-3-일)벤조[b]티오펜-2-카르복사미드 히드로클로리드 모노히드레이트의 결정질 형태
US8513430B2 (en) 2010-07-27 2013-08-20 High Point Pharmaceuticals, Llc Substituted thiazol-2-ylamine derivatives, pharmaceutical compositions, and methods of use as 11-beta HSD1 modulators
EP3461481A1 (en) 2012-05-08 2019-04-03 Forum Pharmaceuticals Inc. Methods of maintaining, treating or improving cognitive function
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神分裂病を処置するための方法および組成物
WO2019236884A1 (en) 2018-06-07 2019-12-12 Disarm Therapeutics, Inc. Inhibitors of sarm1
CA3123215C (en) 2018-12-19 2024-04-02 Disarm Therapeutics, Inc. Inhibitors of sarm1 in combination with neuroprotective agents
KR102629135B1 (ko) 2021-08-19 2024-01-29 단국대학교 천안캠퍼스 산학협력단 Kds2010을 유효성분으로 포함하는 주의력결핍 과잉행동장애의 예방 또는 치료용 약학적 조성물
US20240350471A1 (en) 2021-08-20 2024-10-24 Dankook University Cheonan Campus Industry Academic Cooperation Foundation Pharmaceutical composition for preventing or treating attention deficit/hyperactivity disorder
KR102684933B1 (ko) 2021-08-20 2024-07-16 단국대학교 천안캠퍼스 산학협력단 주의력결핍 과잉행동장애의 진단을 위한 gat-3의 용도
KR102597711B1 (ko) 2021-08-20 2023-11-06 단국대학교 천안캠퍼스 산학협력단 Snap5114을 유효성분으로 포함하는 주의력결핍 과잉행동장애의 예방 또는 치료용 약학적 조성물

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020016334A1 (en) * 2000-07-31 2002-02-07 Coe Jotham Wadsworth Pharmaceutical composition for the treatment of attention deficit hyperactivity disorder (ADHD)
US20030236287A1 (en) * 2002-05-03 2003-12-25 Piotrowski David W. Positive allosteric modulators of the nicotinic acetylcholine receptor

Also Published As

Publication number Publication date
PL377552A1 (pl) 2006-02-06
CR7868A (es) 2005-07-08
EA200500783A1 (ru) 2005-12-29
CA2509142A1 (en) 2004-06-24
BR0317229A (pt) 2005-11-01
NO20053185D0 (no) 2005-06-29
NO20053185L (no) 2005-08-17
US20050107425A1 (en) 2005-05-19
MA27606A1 (fr) 2005-11-01
KR20050085538A (ko) 2005-08-29
MXPA05006336A (es) 2005-08-26
CO5700801A2 (es) 2006-11-30
CN1735441A (zh) 2006-02-15
ZA200504338B (en) 2006-07-26
JP2006510663A (ja) 2006-03-30
IS7858A (is) 2005-05-23
AU2003283656A1 (en) 2004-06-30
OA12969A (en) 2006-10-13
HRP20050522A2 (en) 2005-12-31
EP1572300A1 (en) 2005-09-14
WO2004052461A1 (en) 2004-06-24
AP2005003336A0 (en) 2005-06-30
TNSN05158A1 (fr) 2007-05-14

Similar Documents

Publication Publication Date Title
ECSP055852A (es) Tratamiento del trastorno por déficit de atención con hiperactividad
NL301145I2 (nl) Tirbanibulin
ECSP088221A (es) Agonistas adrenoreceptores alfa2c
ECSP21026021A (es) Moduladores de la expresión de pnpla3
ECSP10010007A (es) Tratamiento con ligandos alpha-7-selectivos
CO2019011265A2 (es) Moduladores de la expresión de pcsk9
DE60034871D1 (de) Verfahren und zusammensetzungen zur prevention oder behandlung von krebs und von krebs assoziertem knochenverlust
MX2021006463A (es) Metodos para el tratamiento de trastornos de expansion repetida de trinucleotidos asociados con actividad msh3.
DK1641456T3 (da) Gaboxadol til behandling af depression og andre affektive lidelser
EA200701995A1 (ru) Способы уменьшения кальцификации
CY1110326T1 (el) Υποκατασταθεισες τετραλινες και ινδανια και η χρηση τους
TW200744567A (en) Phenylethylamine analogs and their use for treating glaucoma
EP4186535A4 (en) GEL MATERIAL FOR TENDON OR LIGAMENT TREATMENT
MX2010001187A (es) Moduladores del receptor ccr9 y metodos para su uso.
BRPI0411174A (pt) combinação do modafinil analéptico e um antidepressivo para o tratamento da depressão
BR112013021035A2 (pt) composições e métodos de reposição de tecido macio aperfeiçoados
ATE397000T1 (de) Tetrahydropyridothiophenen zur verwendung in der behandlung von krebs
EP4072510A4 (en) COMPOSITION FOR LIGHTENING AND/OR WHITENING KERATIN MATERIALS
ATE536874T1 (de) Dreifache monoamin-wiederaufnahmehemmer zur behandlung von chronischen schmerzen
EA200870533A1 (ru) Производные 3-(1н-индол-3-ил)индан-1-иламина для лечения депрессии и тревожности
GB2442365A (en) Methods of determining compounds useful in the treatment of bipolar disorder and methods of treating such disorders
DK1455770T3 (da) Anvendelse af norepinephringenoptagelsesinhibitorer til behandling af tic lidelser
CR7795A (es) Tetralinos e indanes sustitutos
NO20061425L (no) Kombinasjonen av en serotonin-reopptaksinbibitor og loxapin
MX2022003230A (es) Composiciones antitranspirantes.